Results

SMC Announces Marketing Agreement with Plato Technologies. Inc.

Source Node:
Time Stamp: April 19, 2024 5:45 AM - Modified On: April 19, 2024 - Published By:
Source Cluster:
Republished By Plato

  BOCA RATON, FL / Plato / Amplifi / April 18,2024 / SMC Entertainment, Inc. ("SMC" or the "Company") (OTC PINK: SMCE) SMC / (PINK:SMCE) is pleased to announce a marketing agreement and collaboration with Plato Technologies Inc. Plato Technologies specializes in AI content disruption and AI management systems. The collaboration will enable the Company to market Plato's platform directly to web and content development teams. The companies have agreed on a revenue sharing agreement after deducting individual client acquisition costs. "This is just the beginning." stated Erik Blum CEO

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Source Node:
Time Stamp: April 15, 2024 1:26 PM - Modified On: April 15, 2024 - Published By:
Source Cluster:
Republished By Plato

  Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology New York, March 12, 2024 - (Plato Data) - Benzinga has published a new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company's groundbreaking approach to peripheral nervous system (PNS) disorders. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology. The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related

Gome Fin Tech Announced Annual Results of 2023

Source Node:
Time Stamp: April 1, 2024 1:22 PM - Modified On: April 1, 2024 - Published By:
Source Cluster:
Republished By Plato

  Commercial Factoring Progresses Despite Stability Diversified Businesses Ready for Development HONG KONG, Mar 29, 2024 - (ACN Newswire) - Gome Finance Technology Co., Ltd.(Stock Code:628.HK,“Gome Fin Tech”or “the Company”,with its subsidiaries,the“Group”), announced its audited annual results for the year ended 31 December, 2023 (the “Reporting Period”). In 2023, the global geopolitical risks are frequent, the lack of economic recovery momentum and the widening trend of differentiation among countries are highlighted, and the risk spillover from European and US banks under the global high interest rate environment also casts a

Kaskade Finance Closes Successful Pre-Seed Round

Source Node:
Time Stamp: March 11, 2024 3:16 PM - Modified On: March 11, 2024 - Published By:
Source Cluster:
Republished By Plato

Kaskade finance, a gamified incentivization layer protocol, just announced the closure of its pre-seed funding round from over 40 investors. Kaskade Finance Nathan Lenga, CEO of Kaskade, tabled the MVP to go live in August, and to continue to build a world-class team that will make certain Kaskade Finance is the premier liquidity incentivization layer for all of DeFi. The oversubscribed seed round had participation from over 40 investors, some of which include Marshland, NxGen.xyz, Artemis Capital, Andromeda Capital, Hercules Ventures, 369 Capital, Crypto Oasis Ventures, as well as influencers,

Latest Survey from Sotera Digital Reveals Shocking State of Mobile Phone Security in the Workplace.

Source Node:
Time Stamp: February 5, 2024 8:19 AM - Modified On: February 5, 2024 - Published By:
Source Cluster:
Republished By Plato

February 5, 2024, New York - Sotera Digital Security, a leading US based provider of secure communications solutions, has today released its findings from a survey it conducted among over 1,000 senior personnel of large businesses and multinational corporations across the globe. Sectors covered by the survey participants focused on those that require the need for ultra-secure and private communications - both regionally and worldwide - with clients, colleagues and suppliers; namely legal, pharmaceutical, media and corporate affairs, government, and blockchain / AI tech specialists. The survey results provide key

[Mirror] Quadratic Arithmetic Programs: from Zero to Hero

Source Node:
Time Stamp: February 2, 2024 10:43 AM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

Vitalik Buterin via the Vitalik Buterin Blog This is a mirror of the post at https://medium.com/@VitalikButerin/quadratic-arithmetic-programs-from-zero-to-hero-f6d558cea649 There has been a lot of interest lately in the technology behind zk-SNARKs, and people are increasingly trying to demystify something that many have come to call "moon math" due to its perceived sheer indecipherable complexity. zk-SNARKs are indeed quite challenging to grasp, especially due to the sheer number of moving parts that need to come together for the whole thing to work, but if we break the technology down piece by piece then

Plato Data Intelligence Leverages Vectara to Power its Data-As-A-Service / DaaS Platform

Source Node:
Time Stamp: January 18, 2024 1:36 PM - Modified On: January 18, 2024 - Published By:
Source Cluster:
Republished By Plato

From development to launch, Vectara’s GenAI technology and team help innovators get to market faster. The announced partnership breaks new ground towards deploying a next generation of GenAI tools with Vertical focus. Vectara, the Trusted Generative AI Product Platform, and Plato Data Intelligence, creators of PlatoAi, have entered into a commercial agreement to unlock the power of Vectara via Plato AI’s Generative Intelligence platform. With an emphasis on secure, trustworthy, and transparent GenAI for enterprises, Vectara was the clear choice for developers who want a trusted provider to count on

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

GPO Plus, Inc. (GPOX) Achieves Record Revenues with 25% Quarterly Growth

Source Node:
Time Stamp: December 18, 2023 1:36 PM - Modified On: December 18, 2023 - Published By:
Source Cluster:
Republished By Plato

December 18, 2023 - GPO Plus, Inc. (OTCQB: GPOX), a prominent distribution and manufacturing company specializing in consumer products for convenience stores, gas stations, and specialty retailers, has reported impressive Q2 financial results. The company's gross revenue for the quarter ending October 31, 2023, reached a record $1.21 million, marking a substantial 25% increase from the previous quarter ending July 31, 2023, which reported $970,735 in gross revenues. Key Highlights: Quarterly Revenue Surge: GPOX achieved a remarkable 25% surge in top-line revenue, reaching $1.213 million in the second quarter, up

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:17 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis